31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In our dataset search, we identified 108 910 people with a record indicating dementia at any time. 5 key findings →
Design: cohort study Participants: 9,819 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 393 497 All of Us participants with linked EHRs, we identified 9444 individuals (2.40%) with glaucoma diagnoses (excluding participants with diagnoses of dementia before glaucoma) and 37 776 matched controls without glaucoma. 5 key findings →
Design: cohort study Participants: 5,756 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In Fine-Gray models, dementia risk was higher in female than in male participants (subdistribution hazard ratio [sHR] 1·89, 95% CI 1·30-2·76) and Black than Asian participants (sHR 1·75, 1·07-2·88), lower in APOE ε2 carriers than in non-carriers (sHR 0·39, 0·17-0·88), and not significantly higher in APOE ε4 carriers than in non-carriers (sHR 1·51, 0·92-2·47). 3 key findings →
Design: cohort Participants: 805 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This cohort study evaluates the prevalence of dementia diagnoses among US adults with autism spectrum disorder. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 24 762 people with HIV and 494 963 people without HIV (86.9% men, 45.5% White, 23.1% Black, 20.3% Hispanic), incident dementia diagnoses declined from 2000 to 2023 in both people with and without HIV (-7.68 and -2.70% per period, respectively). 5 key findings →
Design: retrospective cohort Participants: 762 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
After 3.5 years of follow up, 19 new cases of dementia were identified among 229 surviving participants. 5 key findings →
Design: cohort study Participants: 341 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 2,218 participants, 237 (11%) developed dementia in the period 1992/3 to 2015/6. 5 key findings →
Design: cohort study Participants: 2,218 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The incidence of dementia was 0.68 (95% CI 0.64-0.72) cases per 100 person-years in pSS, and it was 0.58 (0.56-0.60) in the controls. 5 key findings →
Design: cohort study Participants: 20,160 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The moderate to high isolation group demonstrated a significantly elevated risk of dementia compared with the low isolation group. 5 key findings →
Design: cohort study Participants: 8,189 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 1 268 599 participants (mean age, 73.9 [SD, 6.1] years; n = 25 335 [2%] female), dementia incidence rates per 1000 person-years were lowest in the Mid-Atlantic (11.2; 95% CI, 11.1-11.4) and highest in the Southeast (14.0; 95% CI, 13.8-14.2). 5 key findings →
Design: cohort study Participants: 25 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 331,731 participants (mean ± SD age, 56.53 ± 8.1 years; 156,762 [47.26 %] male), 4413 (1.33 %) developed dementia during a mean follow-up of 12.8 years. 5 key findings →
Design: cohort study Participants: 331,731 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Falls are an early sign of dementia risk, and genetic susceptibility facilitates this association. 4 key findings →
Design: longitudinal study Participants: 265,416 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Adjudicated AKI, which was largely mild and reversible, was independently associated with increased risk of probable dementia and the composite of probable dementia and MCI in older adults at high cardiovascular risk. 5 key findings →
Design: cohort study Participants: 270 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We conducted a retrospective cohort study using the National Health Insurance Database in South Korea. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 1661), 622 developed dementia within 5 years. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Nun Study is an iconic longitudinal study of aging and dementia on a cohort of 678 Catholic nuns from the School Sisters of Notre Dame. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study included 212 patients, with a mean age of 82.27 years. 5 key findings →
Design: cohort study Participants: 212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundWith increasing population longevity, Alzheimer's disease and dementia have become a health priority, and high-quality incidence estimates are needed. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There was a significant difference in dementia incidence in the HSV-infected group versus the control. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over the last decade, age-standardised dementia incidence estimated rates have decreased by 52.8 % for women and 53.1 % for males. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found positive associations between the 15 PM 2.5 components and the incidence of dementia and AD. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We assessed 452,718 patients (mean age: 67.16 years). 3 key findings →
Design: cohort study Participants: 452,718 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Per- and polyfluoroalkyl substances (PFAS) are ubiquitous persistent organic pollutants. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During a mean follow-up of 2.49 years (median, 1.99; standard deviation, 2.07; interquartile range, 2.66), dementia was significantly associated with increased stroke risk (aHR, 3.19; 95% confidence interval, 2.84-3.57). 5 key findings →
Design: cohort study Participants: 2,820 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among a cohort of 118 006 individuals, the incident rate (IR) of dementia was 0.56/1000 person-years over a median follow-up period of 1.54 years among SGLT-2i users compared with 2.67/1000 person-years in DPP-4i users, over a median follow-up period of 1.79 years. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events